PL3256476T3 - Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń oun - Google Patents
Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń ounInfo
- Publication number
- PL3256476T3 PL3256476T3 PL16708260T PL16708260T PL3256476T3 PL 3256476 T3 PL3256476 T3 PL 3256476T3 PL 16708260 T PL16708260 T PL 16708260T PL 16708260 T PL16708260 T PL 16708260T PL 3256476 T3 PL3256476 T3 PL 3256476T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazolo
- analogs
- cns disorders
- treating cns
- oxazinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562115043P | 2015-02-11 | 2015-02-11 | |
PCT/US2016/017527 WO2016130790A1 (en) | 2015-02-11 | 2016-02-11 | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
EP16708260.1A EP3256476B1 (en) | 2015-02-11 | 2016-02-11 | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3256476T3 true PL3256476T3 (pl) | 2019-05-31 |
Family
ID=55456906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16708260T PL3256476T3 (pl) | 2015-02-11 | 2016-02-11 | Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń oun |
Country Status (21)
Country | Link |
---|---|
US (4) | US9758529B2 (pl) |
EP (3) | EP3539967A1 (pl) |
JP (4) | JP6561128B2 (pl) |
KR (1) | KR102623321B1 (pl) |
CN (2) | CN111171047B (pl) |
AU (3) | AU2016219247B2 (pl) |
BR (1) | BR112017017349B1 (pl) |
CA (1) | CA2976092A1 (pl) |
DK (1) | DK3256476T3 (pl) |
EA (1) | EA201791802A1 (pl) |
ES (1) | ES2712627T3 (pl) |
IL (2) | IL253907B (pl) |
MX (1) | MX371197B (pl) |
NZ (1) | NZ734972A (pl) |
PH (1) | PH12017501423A1 (pl) |
PL (1) | PL3256476T3 (pl) |
PT (1) | PT3256476T (pl) |
SG (1) | SG11201706516WA (pl) |
UA (1) | UA123262C2 (pl) |
WO (1) | WO2016130790A1 (pl) |
ZA (1) | ZA201706074B (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018023072A2 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
SG10202100751YA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
KR101753092B1 (ko) | 2016-12-14 | 2017-07-04 | 성일하이텍(주) | 리튬 함유 폐액으로부터 인산리튬 제조방법 |
US10850989B2 (en) | 2016-12-20 | 2020-12-01 | Sungeel Hitech Co., Ltd. | Method for preparing solid lithium salt from lithium solution |
MA49524A (fr) | 2017-06-30 | 2021-05-26 | Chase Therapeutics Corp | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression |
BR112020001433A2 (pt) | 2017-08-02 | 2020-07-28 | Sunovion Pharmaceuticals Inc. | compostos de isocromano e usos dos mesmos |
WO2019236808A1 (en) | 2018-06-07 | 2019-12-12 | Sunovion Pharmaceuticals Inc. | Salts of a oxazino[4,3-b]indazole derivative and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
CA3130849A1 (en) | 2019-03-14 | 2020-09-17 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
TW202237622A (zh) | 2020-12-04 | 2022-10-01 | 美商蘇諾維恩藥業公司 | 雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物 |
US20240158416A1 (en) * | 2021-04-08 | 2024-05-16 | Sumitomo Pharma America, Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
WO2023064768A1 (en) * | 2021-10-11 | 2023-04-20 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3995052A (en) * | 1973-07-09 | 1976-11-30 | Ayerst Mckenna And Harrison Ltd. | Indenopyran- and indenothiopyranalkylamines III in the treatment of depression |
US4041169A (en) * | 1975-03-05 | 1977-08-09 | Ayerst Mckenna And Harrison Ltd. | Pharmaceutical method for using pyrano-and thiopyranoindole derivatives |
MX2008013053A (es) * | 2006-04-12 | 2008-10-17 | Wyeth Corp | Derivados de dihidri[1,4]oxazino[2,3,4-hi]indazol-sustituidos como ligandos de 5-hidroxitriptamina-6. |
CN102388043A (zh) * | 2009-02-11 | 2012-03-21 | 桑诺维恩药品公司 | 组胺h3反相激动剂和拮抗剂及其使用方法 |
RU2641648C1 (ru) * | 2009-12-04 | 2018-01-19 | Суновион Фармасьютикалз, Инк. | Полициклические соединения и способы их применения |
CN105859735B (zh) * | 2010-12-16 | 2018-03-09 | 霍夫曼-拉罗奇有限公司 | 三环pi3k抑制剂化合物和使用方法 |
KR20140082765A (ko) * | 2011-10-05 | 2014-07-02 | 에프. 호프만-라 로슈 아게 | V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌 |
US9365588B2 (en) * | 2011-11-04 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Benzoxazines as modulators of ion channels |
CA2860008C (en) * | 2011-12-22 | 2020-11-10 | Dominique Swinnen | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
AU2013277155A1 (en) * | 2012-06-20 | 2015-01-22 | Vanderbilt University | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors |
JP2014214130A (ja) * | 2013-04-26 | 2014-11-17 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体を含有する医薬 |
NZ735011A (en) * | 2015-02-11 | 2023-07-28 | Sunovion Pharmaceuticals Inc | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
-
2016
- 2016-02-11 WO PCT/US2016/017527 patent/WO2016130790A1/en active Application Filing
- 2016-02-11 CN CN202010051639.8A patent/CN111171047B/zh active Active
- 2016-02-11 NZ NZ734972A patent/NZ734972A/en unknown
- 2016-02-11 CA CA2976092A patent/CA2976092A1/en active Pending
- 2016-02-11 EA EA201791802A patent/EA201791802A1/ru unknown
- 2016-02-11 BR BR112017017349-2A patent/BR112017017349B1/pt active IP Right Grant
- 2016-02-11 JP JP2017542400A patent/JP6561128B2/ja active Active
- 2016-02-11 PT PT16708260T patent/PT3256476T/pt unknown
- 2016-02-11 ES ES16708260T patent/ES2712627T3/es active Active
- 2016-02-11 UA UAA201708954A patent/UA123262C2/uk unknown
- 2016-02-11 AU AU2016219247A patent/AU2016219247B2/en not_active Expired - Fee Related
- 2016-02-11 SG SG11201706516WA patent/SG11201706516WA/en unknown
- 2016-02-11 KR KR1020177025289A patent/KR102623321B1/ko active IP Right Grant
- 2016-02-11 MX MX2017010362A patent/MX371197B/es active IP Right Grant
- 2016-02-11 CN CN201680018684.5A patent/CN107567454B/zh active Active
- 2016-02-11 US US15/041,827 patent/US9758529B2/en active Active
- 2016-02-11 EP EP18213435.3A patent/EP3539967A1/en not_active Withdrawn
- 2016-02-11 EP EP16708260.1A patent/EP3256476B1/en active Active
- 2016-02-11 PL PL16708260T patent/PL3256476T3/pl unknown
- 2016-02-11 EP EP21198192.3A patent/EP4006039B1/en active Active
- 2016-02-11 DK DK16708260.1T patent/DK3256476T3/en active
-
2017
- 2017-08-02 US US15/666,719 patent/US20180057506A1/en not_active Abandoned
- 2017-08-08 IL IL253907A patent/IL253907B/en active IP Right Grant
- 2017-08-09 PH PH12017501423A patent/PH12017501423A1/en unknown
- 2017-09-06 ZA ZA2017/06074A patent/ZA201706074B/en unknown
-
2019
- 2019-05-06 US US16/403,734 patent/US20200024286A1/en not_active Abandoned
- 2019-07-22 JP JP2019134260A patent/JP6928629B2/ja active Active
-
2020
- 2020-09-29 IL IL277658A patent/IL277658B/en unknown
- 2020-11-11 AU AU2020267209A patent/AU2020267209A1/en not_active Abandoned
-
2021
- 2021-02-19 US US17/179,477 patent/US20210300942A1/en not_active Abandoned
- 2021-08-06 JP JP2021129696A patent/JP2021183624A/ja not_active Ceased
-
2022
- 2022-10-28 AU AU2022259828A patent/AU2022259828A1/en active Pending
- 2022-12-02 JP JP2022193341A patent/JP2023036611A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277658A (en) | Dehydrated compounds of dihydro-4H-pyrazolo [5, 1, -C] [1, 4] oxazinyl and their analogues for the treatment of CNS disorders | |
IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
HK1259336A1 (zh) | 用於治療骨髓增生性病症的方法 | |
HK1252978A1 (zh) | 用於治療神經肌肉病癥的化合物 | |
IL275506A (en) | Preparations and methods for the treatment of central nervous system disorders | |
IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
LT3250210T (lt) | Kompozicijos ir būdai, skirti gydyti cns sutrikimus | |
HUE051488T2 (hu) | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére | |
HUE049014T2 (hu) | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére | |
HK1256036A1 (zh) | 治療骨髓增生性障礙的方法 | |
IL275562A (en) | Preparations and methods for the treatment of central nervous system disorders | |
IL253914B (en) | 1-Heterocyclyl isochromanyl compounds and analogs for the treatment of CNS disorders | |
SG10201913400QA (en) | Methods for treating lung disorders | |
EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
HK1256825A1 (zh) | 取代的5,6-二氫-6-苯基苯並[f]異喹啉-2-胺化合物的固體形式 | |
PT3420084T (pt) | Nova abordagem para tratamento de disfunções inflamatórias | |
EP3424506A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNCTIONAL PSYCHIATRIC DISORDER |